Infectious diseases researcher wins $1.225 million fellowship

November 11, 2014

Dr Marc Pellegrini is one of three researchers to this year be awarded a 2014 Sylvia and Charles Viertel Charitable Foundation Senior Medical Research Fellowship.

The fellowships support mid-career medical researchers whose work is likely to have an enormous impact on medical research in the future. Each fellow receives $1.225 million ($245,000 per year for five years).

Dr Pelligrini, a laboratory head in the institute's Infection and Immunity division, said the five-year fellowship would allow him to focus on progressing his research into chronic infections such as HIV, hepatitis B and tuberculosis.

"We have made some significant discoveries about how the microbes that cause these diseases evade the immune system and are now exploring how these discoveries could be applied to eradicate hepatitis B, HIV and tuberculosis," he said. "Research is a long-term proposition so having the security of the Viertel Fellowship to allow us to move our work through to clinical trials is incredibly important."

The Chair of the Viertel Foundation's Medical Advisory Board, Professor Peter Leedman, said the researchers were selected from a strong field of candidates from across Australia.

"The research projects being pursued by these early career scientists cross broad themes from infectious disease and clinical trials in hepatitis B to the earliest stages of development and capturing that in real time, as well as deciphering the detail of the genome, and in particular, the epigenome and the secrets it has for understanding and reshaping brain function," he said.

"In recognition of the extraordinary calibre of the shortlisted candidates this year, the trustees of the foundation agreed to award one more fellowship than normal this year. I thank the trustees for supporting Australian science in this way. This major award will make a significant contribution to their careers and research impact."

The two other recipients of the fellowships were Professor Ryan Lister from the Harry Perkins Institute of Medical Research and the University of Western Australia, and Dr Nicolas Plachta from EMBL Australia and the Australian Regenerative Medicine Institute.
-end-


Walter and Eliza Hall Institute

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.